Elutia (NASDAQ:ELUT – Get Free Report) and enGene (NASDAQ:ENGN – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.
Earnings & Valuation
This table compares Elutia and enGene”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Elutia | $24.38 million | 3.51 | -$37.66 million | ($2.47) | -0.85 |
| enGene | N/A | N/A | -$55.14 million | ($1.52) | -2.61 |
Elutia has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Elutia | 0 | 0 | 2 | 0 | 3.00 |
| enGene | 0 | 1 | 7 | 1 | 3.00 |
Elutia presently has a consensus price target of $9.00, indicating a potential upside of 328.57%. enGene has a consensus price target of $24.13, indicating a potential upside of 509.22%. Given enGene’s higher possible upside, analysts plainly believe enGene is more favorable than Elutia.
Risk & Volatility
Elutia has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.38, suggesting that its stock price is 138% less volatile than the S&P 500.
Profitability
This table compares Elutia and enGene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Elutia | -218.72% | N/A | -142.61% |
| enGene | N/A | -16.69% | -14.27% |
Insider and Institutional Ownership
74.0% of Elutia shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 40.8% of Elutia shares are held by insiders. Comparatively, 13.7% of enGene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Elutia beats enGene on 7 of the 13 factors compared between the two stocks.
About Elutia
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.
